Quantbot Technologies LP Acquires Shares of 144 Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Quantbot Technologies LP bought a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 144 shares of the biopharmaceutical company’s stock, valued at approximately $151,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. Brown Lisle Cummings Inc. lifted its stake in Regeneron Pharmaceuticals by 18.2% in the second quarter. Brown Lisle Cummings Inc. now owns 65 shares of the biopharmaceutical company’s stock valued at $68,000 after buying an additional 10 shares during the last quarter. Sachetta LLC raised its position in Regeneron Pharmaceuticals by 71.4% in the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 10 shares during the last quarter. Adirondack Trust Co. boosted its stake in Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company’s stock worth $453,000 after purchasing an additional 10 shares during the period. UMB Bank n.a. grew its position in Regeneron Pharmaceuticals by 1.1% during the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company’s stock worth $955,000 after purchasing an additional 10 shares during the last quarter. Finally, Western Financial Corp CA increased its stake in Regeneron Pharmaceuticals by 0.7% in the second quarter. Western Financial Corp CA now owns 1,819 shares of the biopharmaceutical company’s stock valued at $1,912,000 after purchasing an additional 12 shares during the period. 83.31% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. Truist Financial dropped their price target on Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating on the stock in a research report on Friday, November 1st. BMO Capital Markets lowered their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Royal Bank of Canada dropped their price objective on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Wolfe Research assumed coverage on shares of Regeneron Pharmaceuticals in a research note on Friday, November 15th. They set an “outperform” rating and a $1,150.00 price target on the stock. Finally, Oppenheimer reduced their price objective on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating for the company in a research report on Wednesday, November 6th. One analyst has rated the stock with a sell rating, four have given a hold rating, seventeen have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Regeneron Pharmaceuticals has a consensus rating of “Moderate Buy” and an average price target of $1,107.29.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $767.90 on Friday. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The stock has a market cap of $84.38 billion, a price-to-earnings ratio of 19.00, a price-to-earnings-growth ratio of 2.89 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $735.95 and a fifty-two week high of $1,211.20. The business has a fifty day moving average of $882.14 and a 200-day moving average of $1,013.01.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.